Comparative Pharmacology
Head-to-head clinical analysis: MACROBID versus UROBAK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACROBID versus UROBAK.
MACROBID vs UROBAK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitrofurantoin is a urinary tract antibacterial agent that inhibits bacterial acetyl-CoA carboxylase, disrupting cell wall synthesis and bacterial respiration. It is reduced by bacterial nitroreductases to reactive intermediates that damage DNA, ribosomes, and other macromolecules.
UROBAK (methenamine hippurate) is a prodrug that hydrolyzes to formaldehyde in acidic urine (pH ≤ 5.5). Formaldehyde denatures bacterial proteins and nucleic acids, exerting a broad-spectrum bacteriostatic effect. The hippurate component may enhance urinary acidification.
100 mg orally twice daily with food for 7 days.
500 mg orally once daily
None Documented
None Documented
Terminal elimination half-life: 0.3-1.0 hour (short) due to rapid renal clearance and tissue metabolism; no accumulation with twice-daily dosing. The short half-life is adequate for urinary tract exposure.
6-8 hours (prolonged in renal impairment).
Renal: 36% (unchanged nitrofurantoin) and 15% (metabolites) within 24 hours. Total renal elimination: 51%. Biliary/fecal: 1-2%. Additional 30% undergoes rapid metabolic degradation in tissues.
Primarily renal (85% unchanged); 15% biliary/fecal.
Category C
Category C
Urinary Anti-infective
Urinary Anti-infective